原料药 API

An oral single-dose agent with a wholly new mechanism against antimicrobial-resistant gonorrhea, a WHO-priority AMR direction with clear public-health procurement demand.

A capsid-binding inhibitor of rhinovirus that can reduce hospitalizations from COPD/asthma exacerbations, a scarce causal-therapy attempt in respiratory care.

A TGF-beta pathway inhibitor valuable both as an immuno-oncology combination component and in fibrosis, a dual-track development asset.

A broad-spectrum fluoroquinolone with extensive clinical experience and controllable cost, suited as a mature generic supply for regional markets.

A novel nucleoside reverse-transcriptase translocation inhibitor (NRTTI) with long-acting dosing, the core evolution of HIV treatment and prevention, high strategic value.

A broad-spectrum triazole covering both aspergillus and mucor, for critical deep fungal infections in immunocompromised patients, an ICU/hematology must-have replacing amphotericin B.

The first novel-mechanism inhaled COPD maintenance therapy in over a decade, combining bronchodilation and anti-inflammation, filling the gap after triple therapy.

A China-originated ALK inhibitor with globally competitive efficacy and safety, a mature asset for domestic innovative-drug export and licensing.

An ATR inhibitor targeting the DNA-damage-repair pathway, a hot combination strategy with chemo-radiotherapy and PARP inhibitors, strong pipeline extensibility.

An NS5B nucleotide analog with pangenotypic activity and a high resistance barrier, an important component of HCV combination and retreatment regimens.

A second-generation XPO1 inhibitor with improved tolerability over the first generation, offering a clear substitution opportunity in elderly AML/MDS.

A voltage-gated sodium-channel modulator for epilepsy; antiepileptic demand is stable in emerging markets, suited as a long-term mature product reserve.

A dual-receptor antagonist expected to further improve efficacy and sleep versus first-generation NK3 agents; a validated segment with large demand.

A selective NR2B-subtype antagonist with fewer psychotropic side effects than traditional NMDA antagonists, a common tool compound for neuroscience research.

An NK1-receptor-route candidate for mood disorders; psychiatric drugs have long cycles and rigid demand, offering differentiated mechanistic value.

Modulates neurosteroid synthesis via the TSPO pathway, avoiding benzodiazepine dependence, a non-sedating new direction in anxiolysis.

The world's first once-weekly oral DPP-4 inhibitor, markedly improving adherence; suited to fixed-dose combination with metformin and aligned with chronic-disease management policy.

An oral small-molecule (non-peptide) GLP-1 agonist, synthetically scalable versus peptide APIs, the most watched next-generation weight-management molecule.

An SHP2 inhibitor confronting KRAS/EGFR resistance, a core combination partner with KRAS inhibitors and EGFR antibodies.

An A2A adenosine-receptor antagonist spanning both neurodegeneration and tumor immunotherapy, a dual-scenario molecule with rising research interest.

The mTOR pathway is a core resistance mechanism in breast and gynecologic cancers; combination regimens with endocrine therapy continue to advance.

A classic cholecystokinin-receptor antagonist research molecule, commonly used in basic studies of digestion physiology and appetite regulation.

An anti-secretory antidiarrheal that does not inhibit intestinal motility and pairs with rehydration, widely used in pediatric acute diarrhea.

A classic nucleoside reverse-transcriptase inhibitor still anchoring AIDS cocktail therapy; long-term must-have in national public-health procurement.